SCHEMBL4529448

SCHEMBL4529448

Cc1cccc(C)c1C1CCN(Cc2c(-c3ccccc3)n(CC(=O)NC3CC(C)(C)NC(C)(C)C3)c3ccccc23)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
UBE2N P61088 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTT P42858 1/20 0.40
KMT2A Q03164 4/20 0.39
KDM4E B2RXH2 3/20 0.39
POLB P06746 1/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
AVPR1B P47901 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HSD17B10 Q99714 1/20 0.36
DRD4 P21917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4519785 0.91 UBE2N (0.43) UBE2NTDP1KMT2AKDM4EPOLB
SCHEMBL4518521 0.88 UBE2N (0.45) UBE2NTDP1KMT2AKDM4EPOLB
SCHEMBL4522972 0.86 UBE2N (0.45) UBE2NTDP1KMT2AKDM4EPOLB
SCHEMBL4514150 0.85 UBE2N (0.44) UBE2NTDP1KMT2AKDM4EPOLB
Trifluoroacetic Acid SCHEMBL4505995 0.83 UBE2N (0.45) UBE2NTDP1KMT2AKDM4EPOLB
SCHEMBL4521541 0.82 KDM4E (0.45) UBE2NTDP1HTTKMT2AKDM4E
SCHEMBL4514740 0.82 HTR2A (0.39) UBE2NTDP1HTTKMT2AKDM4E
SCHEMBL4518923 0.79 SIGMAR1 (0.48) UBE2NTDP1KMT2APOLBLMNA
SCHEMBL4520660 0.78 TSHR (0.49) KDM4EPOLBTSHRMAPK1AVPR1B
SCHEMBL5421524 0.78 ALDH1A1 (0.42) POLBALDH1A1HSD17B10DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor BRANE DISCOVERY S.R.L. (IT) 2009-11-05 US claimed
EP-1841755-A1 SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR BRANE DISCOVERY S.R.L. (IT) 2007-10-10 EP claimed
WO-2006070001-A1 SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR BRANE DISCOVERY S.R.L. (IT) 2006-07-06 WO claimed
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor BRANE DISCOVERY S.R.L. (IT) 2009-11-05 US disclosed
EP-1841755-A1 SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR BRANE DISCOVERY S.R.L. (IT) 2007-10-10 EP disclosed
WO-2006070001-A1 SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR BRANE DISCOVERY S.R.L. (IT) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor OGFRL1, OPRL1, ORMDL3 UBE2N 2883/4885TDP1 2258/4885HTT 4645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.